Kerecis

Focus: Kerecis is a 501-1000 person biotechnology company headquartered in Iceland specializing in wound healing solutions using fish skin grafts and acellular ECM technologies. The company operates in the dermatology/regenerative medicine space with a portfolio of commercial and clinical-stage products.

Dermatology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Employees

501-1000

Open Jobs

About Kerecis

AI assessmentNot Hiring

No open roles listed right now. Follow Kerecis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

16 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Intact Fish Skin Graft

Venous Leg Ulcer (VLU)

Growth

Phase 4 commercial product addressing significant chronic wound market with strong clinical rationale.

Kerecis Omega3 Wound

Diabetic Foot Ulcer

Help build intelligence for Kerecis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established commercial portfolio with Phase 4 programs in high-burden conditions (VLU, burns, necrotizing fasciitis) generating recurring revenue
Unique biological platform (fish skin grafts with Omega-3 enrichment) offers differentiated IP and clinical validation across 16 pipeline programs
European headquarters + mid-cap size creates lean decision-making and direct impact visibility absent in larger pharma structures

Watch Out For

Zero current job openings (activeJobCount: 0) signals either hiring freeze, full capacity, or organizational stagnation
Early-stage pipeline outside wound care (Phase 1 oral program, COVID spray, gender dysphoria indication) suggests unfocused development strategy with unclear market potential

Generated by Claude from Kerecis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Commercial product leveraging omega-3 enriched fish skin for high-prevalence diabetic complication with repeat dosing potential.

Acellular Fish Skin Graft

Necrotizing Fasciitis

Growth

Phase 4 product for acute severe wound indication with unmet need and potential hospital formulary adoption.

Pipeline & Clinical Trials

Viruxal Oral and Nasal Spray

COVID-19

N/A

Clinical Trials (1)

NCT04357990Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19

N/A

Kerecis™ Omega3 Wound

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT04257370Kerecis Omega3 Wound Plus SOC vs. SOC Alone in Treating Severe Diabetic Foot Ulcers and Forefoot Amputations

N/A

Punch biopsies treated with MariGen Wound ECM dressing

Punch Biopsy Wounds

N/A

Clinical Trials (1)

NCT01917591Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study

N/A

Kerecis Fish Skin Graft

Wounds

N/A

Clinical Trials (1)

NCT06384183Kerecis Real-World Fish Skin Graft Registry

N/A

Prospective Case Registry for Wounds

Wound Healing Delayed

N/A

Clinical Trials (1)

NCT05898698Prospective Case Registry for Wounds

N/A

Fish skin

Burns

N/A

Clinical Trials (1)

NCT03984331Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns

N/A

Evaluating the Durability of Closure for Venous Leg Ulcers

Venous Leg

N/A

Clinical Trials (1)

NCT06697925Evaluating the Durability of Closure for Venous Leg Ulcers

N/A

Kerecis Omega3 Wound

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT04133493Omega3 Wound Fish Skin Graft in the Treatment of DFUs

N/A

Fish skin graft

Surgery-Complications

N/A

Clinical Trials (1)

NCT05898711Kerecis Case Registry for SurgiBind : Soft Tissue Reinforcement

N/A

Tubularized augmented peritoneal cap vaginoplasty

Gender Dysphoria, Adult

N/A

Clinical Trials (1)

NCT07286123Gender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™)

N/A

Kerecis Omega3 Wound

Diabetes

N/A

Clinical Trials (1)

NCT04537520Interventional Clinical Trial Comparing Kerecis Omega3 Wound Versus SOC in Diabetic Foot Wounds

N/A

Marigen Wound Dressing

Pressure Ulcers

N/A

Clinical Trials (1)

NCT01348581Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing

N/A

Kerecis Oral™

Mucogingival Deformity - Insufficient Keratinized Tissue

PHASE_1

Clinical Trials (1)

NCT03664401A Clinical Trial to Evaluate Kerecis Oral™ Compared to Autogenous Free Gingival Graft (AFGG) Tissue to Augment Gingival Soft Tissue and Wound Healing

Phase 1

Intact fish skin graft

Partial-thickness Burn Wounds

PHASE_4

Clinical Trials (1)

NCT07326657Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns

Phase 4

Intact Fish Skin Graft

Venous Leg Ulcer (VLU)

PHASE_4

Clinical Trials (1)

NCT06693570Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers